A Phase 3 interventional study of Semaglutide and Semaglutide in Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 76 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 14th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 56th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 31st largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, and was the 98th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \[mg\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
Drug: Semaglutide
Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
Drug: Semaglutide
Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
Drug: Placebo
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Relative Change in Body Weight
Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)
Number of participants who achieve body weight reduction \>=5% is presented. Yes defines participants who achieved body weight reduction \>= 5% and No defines participants who did not achieve body weight reduction \>=5%.
Time frame: At week 72
Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)
Number of participants who achieve body weight reduction \>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.
Time frame: At week 72
Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)
Number of participants who achieve body weight reduction \>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.
Time frame: At week 72
Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)
Number of participants who achieve body weight reduction \>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.
Time frame: At week 72
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Body Weight
Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Body Mass Index (BMI)
Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline
Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline
Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in HDL Cholesterol (mg/dL) - Ratio to Baseline
Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in LDL Cholesterol (mg/dL) - Ratio to Baseline
Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline
Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Triglycerides (mmol/L) - Ratio to Baseline
Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Triglycerides (mg/dL) - Ratio to Baseline
Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline
Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Free Fatty Acids (mg/dL) - Ratio to Baseline
Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline
Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Fasting Plasma Glucose
Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline
Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline
Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])
Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.
Time frame: At week 72
Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)
Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.
Time frame: At week 72
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)
Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.
Time frame: At week 81
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)
Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.
Time frame: At week 81
Change in Pulse
Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.
Time frame: Baseline (week 0), End of treatment (week 72)
Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.
Time frame: At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs
Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.
Time frame: At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs
Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.
Time frame: At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.
Time frame: At week 81
The trial was conducted at 68 sites in 8 countries.
| Milestone | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Started | 307 | 103 | 102 |
| Full analysis set | 307 | 103 | 102 |
| Safety analysis set | 307 | 103 | 102 |
| Completed | 295 | 100 | 96 |
| Not completed | 12 | 3 | 6 |
| Withdrew: Withdrawal by subject | 5 | 0 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Death | 4 | 1 | 1 |
| Withdrew: Unspecified reason | 0 | 1 | 0 |
Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.
| Percentage (%) change in body weight | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Relative Change in Body Weight | -13.5 ± 8.7 | -10.7 ± 8.1 | -4.0 ± 6.2 |
Number of participants who achieve body weight reduction \>=5% is presented. Yes defines participants who achieved body weight reduction \>= 5% and No defines participants who did not achieve body weight reduction \>=5%.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Yes | 251 | 73 | 33 |
| No | 40 | 24 | 62 |
Number of participants who achieve body weight reduction \>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Yes | 183 | 50 | 11 |
| No | 108 | 47 | 84 |
Number of participants who achieve body weight reduction \>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Yes | 120 | 28 | 7 |
| No | 171 | 69 | 88 |
Number of participants who achieve body weight reduction \>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Yes | 62 | 14 | 2 |
| No | 229 | 83 | 93 |
Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.
| Centimeters (cm) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Waist Circumference | -12.6 ± 10.5 | -10.6 ± 8.4 | -6.5 ± 10.6 |
Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.
| Percentage of HbA1c | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -1.8 ± 1.2 | -1.7 ± 1.0 | -0.3 ± 1.3 |
Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.
| Kilograms (kg) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Body Weight | -14.9 ± 10.6 | -11.4 ± 8.9 | -4.6 ± 7.1 |
Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.
| kilograms per meter square (kg/m^2) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Body Mass Index (BMI) | -5.3 ± 3.8 | -4.1 ± 3.3 | -1.6 ± 2.5 |
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.
| Millimeters of mercury (mmHg) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Systolic Blood Pressure | -8 ± 13 | -7 ± 15 | -3 ± 13 |
Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.
| mmHg | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Diastolic Blood Pressure | -3 ± 9 | -3 ± 10 | -3 ± 9 |
Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of total cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline | 0.96 ± 23.0 | 0.96 ± 21.1 | 0.97 ± 28.3 |
Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of total cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline | 0.96 ± 23.0 | 0.96 ± 21.1 | 0.97 ± 28.3 |
Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of HDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline | 1.10 ± 17.8 | 1.06 ± 13.5 | 1.07 ± 16.1 |
Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of HDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in HDL Cholesterol (mg/dL) - Ratio to Baseline | 1.10 ± 17.8 | 1.06 ± 13.5 | 1.07 ± 16.1 |
Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of LDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline | 0.99 ± 40.1 | 0.95 ± 36.5 | 0.97 ± 41.4 |
Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of LDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in LDL Cholesterol (mg/dL) - Ratio to Baseline | 0.99 ± 40.1 | 0.95 ± 36.5 | 0.97 ± 41.4 |
Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of VLDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline | 0.72 ± 42.5 | 0.81 ± 40.4 | 0.90 ± 47.8 |
Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of VLDL cholesterol | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline | 0.72 ± 42.5 | 0.81 ± 40.4 | 0.90 ± 47.8 |
Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of triglycerides | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Triglycerides (mmol/L) - Ratio to Baseline | 0.71 ± 46.2 | 0.80 ± 42.2 | 0.87 ± 54.4 |
Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of triglycerides | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Triglycerides (mg/dL) - Ratio to Baseline | 0.71 ± 46.2 | 0.80 ± 42.2 | 0.87 ± 54.4 |
Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of free fatty acids | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Free Fatty Acids (mmol/L) - Ratio to Baseline | 0.74 ± 69.8 | 0.81 ± 70.6 | 0.98 ± 65.8 |
Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of free fatty acids | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Free Fatty Acids (mg/dL) - Ratio to Baseline | 0.74 ± 69.8 | 0.81 ± 70.6 | 0.98 ± 65.8 |
Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of hsCRP | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline | 0.47 ± 166.7 | 0.48 ± 121.1 | 0.82 ± 96.0 |
Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.
| mg/dL | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Fasting Plasma Glucose | -59.6 ± 53.1 | -58.4 ± 46.3 | -20.2 ± 68.7 |
Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of fasting serum insulin | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline | 0.77 ± 66.5 | 0.90 ± 70.6 | 0.87 ± 71.4 |
Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.
| Ratio of fasting serum insulin | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline | 0.77 ± 66.5 | 0.90 ± 70.6 | 0.87 ± 71.4 |
Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol]) | 235 | 75 | 27 |
Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.
| Participants | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol) | 209 | 64 | 15 |
Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.
| Events | Semaglutide 7.2 mg | Placebo |
|---|---|---|
| Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs) | 1581 | 253 |
Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.
| Events | Semaglutide 7.2 mg | Placebo |
|---|---|---|
| Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs) | 39 | 21 |
Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.
| Beats per minute (bpm) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Change in Pulse | 1 ± 10 | 2 ± 10 | -4 ± 9 |
Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.
| Episodes | Semaglutide 7.2 mg | Placebo |
|---|---|---|
| Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes | 0 | 1 |
Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.
| Events | Semaglutide 7.2 mg | Semaglutide 2.4 mg |
|---|---|---|
| Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs | 1581 | 508 |
Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.
| Events | Semaglutide 7.2 mg | Semaglutide 2.4 mg |
|---|---|---|
| Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs | 39 | 35 |
Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.
| Episodes | Semaglutide 7.2 mg | Semaglutide 2.4 mg |
|---|---|---|
| Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes | 0 | 0 |
Collected over From week 0 to week 81. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide 7.2 mg | 4/307 (1.3%) | 30/307 (9.8%) | 187/307 (60.9%) |
| Semaglutide 2.4 mg | 1/103 (1%) | 11/103 (10.7%) | 64/103 (62.1%) |
| Placebo | 1/102 (1%) | 10/102 (9.8%) | 40/102 (39.2%) |
| Event | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/307 | 2/103 | 3/102 |
| NephrolithiasisRenal and urinary disorders | 0/307 | 2/103 | 0/102 |
| Acute kidney injuryRenal and urinary disorders | 0/307 | 1/103 | 1/102 |
| AnaemiaBlood and lymphatic system disorders | 0/307 | 0/103 | 1/102 |
| Aortic aneurysmVascular disorders | 0/307 | 0/103 | 1/102 |
| Bell's palsyNervous system disorders | 0/307 | 0/103 | 1/102 |
| Cardiac arrestCardiac disorders | 0/307 | 0/103 | 1/102 |
| Carotid artery stenosisNervous system disorders | 0/307 | 0/103 | 1/102 |
| Chest painGeneral disorders | 0/307 | 0/103 | 1/102 |
| CholelithiasisHepatobiliary disorders | 0/307 | 0/103 | 1/102 |
| Event | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 89/307 | 29/103 | 12/102 |
| DiarrhoeaGastrointestinal disorders | 56/307 | 21/103 | 9/102 |
| ConstipationGastrointestinal disorders | 45/307 | 19/103 | 5/102 |
| VomitingGastrointestinal disorders | 51/307 | 14/103 | 3/102 |
| Upper respiratory tract infectionInfections and infestations | 17/307 | 9/103 | 5/102 |
| DyspepsiaGastrointestinal disorders | 25/307 | 4/103 | 2/102 |
| NasopharyngitisInfections and infestations | 9/307 | 3/103 | 8/102 |
| Decreased appetiteMetabolism and nutrition disorders | 21/307 | 8/103 | 5/102 |
| EructationGastrointestinal disorders | 11/307 | 8/103 | 1/102 |
| HeadacheNervous system disorders | 22/307 | 8/103 | 4/102 |
Full analysis set included all randomised participants.
| Age, Continuous(Years) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 57 ± 10 | 58 ± 10 | 55 ± 10 | 56 ± 10 |
| Sex: Female, Male(Participants) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 166 | 47 | 52 | 265 |
| Male | 141 | 56 | 50 | 247 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 16 | 5 | 8 | 29 |
| Not Hispanic or Latino | 291 | 98 | 94 | 483 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 19 | 7 | 6 | 32 |
| Native Hawaiian or Other Pacific Islander | 5 | 0 | 0 | 5 |
| Black or African American | 22 | 13 | 9 | 44 |
| White | 258 | 83 | 87 | 428 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jan 2023 to primary completion in Oct 2024, 21 months.
Results were first posted in Apr 2026, 1 year 5 months after primary completion. A results delay was requested in Oct 2025.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 21 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide